Diabetes, obesity & metabolismFeb 5, 2025

iGlarLixi and daily blood sugar control in insulin-naive adults with poorly controlled type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jan 20, 2026

Abstract

Treatment with iGlarLixi resulted in a 26.2% increase in for patients with type 2 diabetes and high HbA1c levels.

Participants experienced a reduction in mean daily blood glucose by 52.5 mg/dL after 16 weeks.
Maximum postprandial glucose levels decreased by 73.7 mg/dL four hours after breakfast.
for blood glucose levels greater than 180 mg/dL decreased by 28.7%.
Rates of level 1 hypoglycaemia were reported at 1.4 events per person-year, and level 2 at 0.6 events per person-year.
No severe hypoglycaemia events, which require assistance, were reported during the study.

Simplified

AIMS: People with type 2 diabetes (T2D) and glycated haemoglobin (HbA1c) ≥9% may benefit from fixed-ratio combination therapies such as iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL). Use of continuous glucose monitoring (CGM) is recommended, but data are lacking to assess the impact of iGlarLixi in individuals with HbA1c ≥9%.

MATERIALS AND METHODS: Soli-CGM (NCT05114590) was a 16-week, multicentre, open-label study evaluating the efficacy of once-daily iGlarLixi using blinded CGM-based metrics in insulin-naive adults with HbA1c ≥9%-13% who were receiving ≥2 oral antihyperglycaemic agents (OADs) ± glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The primary outcome was the change from baseline to week 16 in percent (TIR; 70-180 mg/dL). Secondary outcomes included change in mean daily blood glucose (BG), maximum postprandial glucose 4 h post-breakfast (PPG-4 h), and (TAR; >180 mg/dL). On-treatment hypoglycaemia was assessed.

RESULTS: The study enrolled 124 participants (mean age, 55.6 years; HbA1c, 10.2%). Sixteen weeks of treatment with iGlarLixi improved TIR (+26.2%), mean BG (-52.5 mg/dL), maximum PPG-4 h (-73.7 mg/dL), and TAR (-28.7%); all p < 0.001. Rates of American Diabetes Association level 1 (BG <70 but ≥54 mg/dL) and level 2 (BG <54 mg/dL) hypoglycaemia were reported as 1.4 and 0.6 events per person-year, respectively. No level 3 events (requiring assistance) were reported.

CONCLUSIONS: In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RAs, 16 weeks of treatment with iGlarLixi significantly improved TIR and reduced TAR without severe hypoglycaemia.

Key numbers

26.2%

Increase in ()

increased from 26.44% at baseline to 52.65% at week 16.

52.5 mg/dL

Decrease in Mean Daily Blood Glucose

Mean daily blood glucose decreased significantly over the treatment period.

1.4

Hypoglycaemia Incidence Rate

Level 1 hypoglycaemia events reported as 1.4 events per person-year.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

JPF is an employee of and stockholder in Biomea Fusion, Inc. He reports research support from Akero, Altimmune, Boehringer Ingelheim, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Sanofi, and Shionogi; has participated in advisory boards and provided consultancy for Akero, Altimmune, Biomea Fusion, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Merck, Novo Nordisk, Pfizer, and Sanofi; and has attended speakers bureau for Eli Lilly. ARL has received research support from Sanofi; has been a consultant for Dexcom, Novo Nordisk, and Sanofi; has participated in advisory boards for Sanofi; and has given paid presentations for Abbott, the American Diabetes Association, Dexcom, Diabetes Canada, Eli Lilly, Novo Nordisk, and Sanofi. TD and LM are employees of Sanofi and hold stock options/stock in Sanofi. AR is an employee of Ividata, contracted by Sanofi. VNS reports receiving grant/research support from Alexion, Dexcom, Enable Bioscience, and Novo Nordisk and has received honoraria from Ascensia Diabetes Care, Dexcom, Embecta, Insulet, Genomelink, LumosFit, Novo Nordisk, Sanofi, and Tandem Diabetes Care for speaking, consulting, or advisory work.

PubMed

iGlarLixi and daily blood sugar control in insulin-naive adults with poorly controlled type 2 diabetes

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief